Sermorelin (GHRH 1–29 Amide)
Overview
Sermorelin is the 29-amino-acid N-terminal fragment of growth-hormone-releasing hormone (GHRH 1–29) — the shortest fragment that keeps full GHRH activity. It is a full GHRH-receptor agonist and was historically used as a diagnostic agent for growth-hormone deficiency. In research it is used to probe the somatotropic axis and pituitary GH dynamics. It is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 86168-78-7 |
| Class | GHRH(1–29) fragment, C-terminal amide |
| Amino-acid sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ |
| One-letter code | YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH₂ (29 aa) |
| Molecular formula | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Molecular weight | ≈ 3357.9 g/mol |
| Purity (HPLC) | ≥ 98% |
- Class
- GHRH(1–29) amide fragment
- Research status
- GH research; formerly a diagnostic agent
- Study routes
- Subcutaneous, intravenous
- Half-life
- ≈ 12 min
- Key feature
- Shortest fully active GHRH fragment
Mechanism of Action
Sermorelin reproduces the action of natural GHRH: it binds the GHRH receptor on pituitary somatotrophs and, through Gαs and cAMP, stimulates the synthesis and pulsatile release of growth hormone. Because it works upstream on the pituitary, GH output stays subject to the body’s normal feedback, and it has a very short half-life — the opposite end of the spectrum from CJC-1295.
| Component | Detail |
|---|---|
| Primary target | GHRH receptor (GHRH-R) |
| G-protein coupling | Gαs → adenylyl cyclase → cAMP → PKA |
| GH release | Stimulates natural pulsatile GH secretion |
| Feedback | GH output remains under normal somatostatin feedback |
| Duration | Short-acting (minutes) |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 12 min |
| Bioavailability (SC) | ≈ 60–70% |
| Time to peak (Tmax) | ≈ 15–30 min |
| Metabolism | Proteolytic degradation |
| Route of administration | Subcutaneous, intravenous |
| Elimination | Renal (peptide fragments) |
Research Evidence
Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
| Study type | Research focus | Reference |
|---|---|---|
| GH-stimulation testing | GHRH-receptor agonism / GH-deficiency diagnostics | GHRH / sermorelin clinical literature |
| Somatotropic-axis research | Pituitary GH dynamics and pulsatility | GHRH literature |
| Aging GH-axis research | GH/IGF-1 responses to GHRH | GHRH literature |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Reliable GH release; used in GH-deficiency testing | GH-stimulation testing | GHRH literature |
| Physiological, short-acting GHRH-receptor probe | somatotropic-axis research | GHRH literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 200–500 µg per injection, in study protocols |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Storage (lyophilized) | −20°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to ~2–3 weeks |
| Do not use | If the solution is cloudy or contains particulates |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Local tolerability | Mild injection-site reactions |
| Hormonal | No significant prolactin or cortisol elevation (GHRH mechanism) |
| General | Well tolerated in reported GH-testing use |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white lyophilized powder |
| Solubility (water) | Soluble |
| logP | ≈ −2.5 (hydrophilic) |
| pH (reconstituted) | 5.0–7.0 |
| Stability (lyophilized) | ≥ 24 months at −20°C |
Synthesis & Manufacturing
Sermorelin is a 29-residue C-terminally amidated peptide made by Fmoc solid-phase synthesis. Its length and the single oxidation-sensitive methionine make coupling efficiency and cleavage the steps that need the most care.
| Step | Detail |
|---|---|
| Strategy | Fmoc solid-phase peptide synthesis |
| Resin | Rink amide resin (C-terminal amide) |
| Sensitive residue | Met protected against oxidation; scavengers at cleavage |
| Coupling | HBTU / HOBt with DIPEA |
| Cleavage | TFA / TIPS / H₂O with thiol scavengers |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. A single methionine is oxidation-sensitive; use scavengers at cleavage and protect solutions.
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, reversed-phase TFA/ACN gradient | Single main peak |
| ESI-MS (positive mode) | Identity / mass | [M+H]⁺ ≈ 3358 Da |
| MALDI-TOF | Mass confirmation | [M+H]⁺ ≈ 3358 Da |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 3358 Da). A single methionine is oxidation-sensitive; use scavengers at cleavage and protect solutions.
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 2–8°C, dark | ≥ 12 months | Minimal degradation (purity > 95%) |
| Lyophilized, 25°C (accelerated) | 3 months | < 5% degradation |
| Reconstituted, 2–8°C, dark | 7–14 days | Minor degradation |
| Reconstituted, 25°C | 24–48 h | Use promptly |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Generally light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable — aliquot to avoid repeats |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: A single methionine is oxidation-sensitive; use scavengers at cleavage and protect solutions.
Selected References
- GHRH(1–29) / sermorelin pharmacology and GH-stimulation-test literature.
- Reviews of GHRH analogues and the somatotropic axis.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need Sermorelin — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
